AI diagnostics and what clinicians can verify in oncology

• by Lisa Astor

• October 1, 2026

FDA revises monitoring for SCLC therapy

Initial monitoring decreases from 22 to 24 hours to 6 to 8 hours from the start of the first 2 infusions.

• by Kathryn Wighton

• September 15, 2026

• 2 min

Newborn variants may flag childhood cancer predisposition

Targeted sequencing identified cancer-risk variants in about 7% of pediatric patients who later developed early-onset solid or brain malignancies.

• by Andrea Surnit

• August 28, 2026

• 4 min

FDA expands bladder cancer therapy approval

The expansion offers another treatment option for patients with high-grade tumors following BCG failure.

• by Mouj Hijazi

• October 14, 2026

• 3 min